Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAW Trial: Bupivacaine Infiltration in GI Surgery
NCT02777866Unknown
- Sponsor
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
- Start
- May 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of bupivacaine hydrochloride 0.75% injection in surgical site infection (SSI) and postoperative pain (2 arms), sponsored by Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Primary endpoints: Postoperative Surgical Site Infection at 30 days and Efficacy of 0.5% Bupivacaine Infiltration for Post-op Pain at 48 hours. Status: unknown.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
surgical site infection (SSI)postoperative pain
Beyond the preview
Go deeper on NCT02777866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02777866.